经典型霍奇金淋巴瘤表观遗传学异常及其对免疫逃逸的影响

doi:10.11904/j.issn.1002-3070.2017.01.016

Abstract

Abstract:

The malignant phenotype of classical Hodgkin lymphoma(cHL)is partly maintained by epigenetic aberrant,of which consisted mainly abnormal histone methylation and deacetylation.Progress has been made in clinical trials related to the histone deacetylases inhibitors(HDACis)in cHL.There is a close association noted between the epigenetic aberrants and the immune escape in cHL.DNA methyltransferase(DNMT)inhibitors,HDACis and immune checkpoint blockade have shown synergistic effects.Further study to improve the cure rate in cHL by combination strategy is of significant importance.

Key words: Classical Hodgkin lymphoma, Methylation, Acetylation, Immune escape, Immune checkpoint inhibitor

CLC Number:

R730.5

LIU Xiaojian, LONG Zhiguo, QIAO Zhongjie. Research progress in epigenetic aberrant in classic Hodgkin lymphoma[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 73-77.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2017.01.016

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2017/V31/I1/73

References

1 Swerdlow SH,Campo E,Pileri SA,et al.The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J].Blood,2016,127(20):2375-2390.
2 Salzmann S,Lang I,Rosenthal A,et al.TWEAK inhibits TRAF2-mediated CD40 signaling by destabilization of CD40 signaling complexes[J].J Immunol,2013,191(5):2308-2318.
3 Ushmorov A,Leithuser F,Sakk O,et al.Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma[J].Blood,2006,107(6):2493-2500.
4 Chik F,Szyf M,Rabbani SA.Role of epigenetics in cancer initiation and progression[J].Adv Exp Med Biol,2011,7(20):91-104.
5 Ammerpohl O,Haake A,Pellissery S,et al.Array-based DNA methylation analysis in classical Hodgkin lymphoma reveals new insights into the mechanisms underlying silencing of B cell-specific genes[J].Leukemia,2012,26(4):185-188.
6 Cowan LA,Talwar S,Yang AS.Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors[J].Epigenomics,2010,2(1):71-86.
7 Glozak MA,Sengupta N,Zhang X,et al.Acetylation and deacetylation of non-histone proteins[J].Gene,2005,36(3):15-23.
8 Marmorstein R.Structure and function of histone acetyltransferases[J].Cell Mol Life Sci,2001,58(56):693-703.
9 Morin RD,Mendez-Lago M,Mungall AJ,et al.Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma[J].Nature,2011,476(7360):298-303.
10 Haery L,Thompson RC,Gilmore TD.Histone acetyltransferases and histone deacetylases in B-and T-cell development,physiology and malignancy[J].Genes Cancer,2015,6(6):184-213.
11 Eliseeva ED,Valkov V,Jung M,et al.Characterization of novel inhibitors of histone acetyltransferases[J].Mol Cancer Ther,2007,6(9):2391-2398.
12 Adams H,Fritzsche FR,Dirnhofer S,et al.Class I histone deacetylases 1,2 and 3 are highly expressed in classical Hodgkin's lymphoma[J].Expert Opin Ther Targets,2010,14(6):577-584.
13 West AC,Johnstone RW.New and emerging HDAC inhibitors for cancer treatment[J].J Clin Invest,2014,124(1):30-39.
14 Younes A,Sureda A,Ben-Yehuda D,et al.Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation:results of a phase II study[J].J Clin Oncol,2012,30(18):2197-2203.
15 Younes A,Oki Y,Bociek RG,et al.Mocetinostat for relapsed classical Hodgkin's lymphoma:an open-label,single-arm,phase 2 trial[J].Lancet Oncol,2011,12(13):1222-1228.
16 Gubin MM,Zhang X,Schuster H,et al.Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens[J].Nature,2014,515(7528):577-581.
17 Vardhana S,Younes A.The immune microenvironment in Hodgkin lymphoma:T cells,B cells,and immune checkpoints[J].Haematologica,2016,101(7):794-802.
18 Steidl C,Shah SP,Woolcock BW,et al.MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers[J].Nature,2011,471(7338):377-381.
19 Mehta NT,Truax AD,Boyd NH,et al.Early epigenetic events regulate the adaptive immune response gene CIITA[J].Epigenetics,2011,6(4):516-525.
20 Green MR,Monti S,Rodig SJ,et al.Integrative analysis reveals selective 9p24.1 amplification,increased PD-1 ligand expression,and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma[J].Blood,2010,116(17):3268-3277.
21 Yang H,Bueso-Ramos C,DiNardo C,et al.Expression of PD-L1,PD-L2,PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents[J].Leukemia,2014,28(6):1280-1288.
22 Green MR,Rodig S,Juszczynski P,et al.Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders:implications for targeted therapy[J].Clin Cancer Res,2012,18(6):1611-1618.
23 Li B,Greene MI.FOXP3 actively represses transcription by recruiting the HAT/HDAC complex[J].Cell Cycle,2007,6(12):1432-1436.
24 Ansell SM,Lesokhin AM,Borrello I,et al.PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma[J].N Engl J Med,2015,372(4):311-319.
25 Villasboas JC,Ansell S.Checkpoint inhibition:programmed cell death 1 and programmed cell death 1 ligand inhibitors in hodgkin lymphoma[J].Cancer J,2016,22(1):17-22.
26 Khot A,Dickinson M,Prince HM.Panobinostat in lymphoid and myeloid malignancies[J].Expert Opin Investig Drugs,2013,22(9):1211-1223.
27 Oki Y,Buglio D,Zhang J,et al.Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression[J].Blood Cancer J,2014,4(4):23-26.
28 West AC,Smyth MJ,Johnstone RW.The anticancer effects of HDAC inhibitors require the immune system[J].Oncoimmunology,2014,3(1):27-34.
29 Beg AA,Gray JE.HDAC inhibitors with PD-1 blockade:a promising strategy for treatment of multiple cancer types[J].Epigenomics,2016,8(8):1015-1017.
30 Zheng H,Zhao W,Yan C,et al.HDAC inhibitors enhance T cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma[J].Clin Cancer Res,2016,22(16):4119-4132.
31 Woods DM,Sodre AL,Villagra A,et al.HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade[J].Cancer Immunol Res,2015,3(12):1375-1385.

[1]	LI Xiaotong, MIAO Miao, HOU Kaijiong, CHEN Hong. Research progress in the impact of GATA4 on tumors [J]. Journal of Practical Oncology, 2025, 39(4): 338-342.
[2]	LI Dongsheng, LI Zehao, CHEN Yonggang. Application of DNA methylation risk scoring model for ferroptosis related genes in the prognosis and immune feature assessment of colon cancer [J]. Journal of Practical Oncology, 2025, 39(3): 224-234.
[3]	WANG Mengfei, XU Boqun. Advances in immunotherapy for locally advanced cervical cancer [J]. Journal of Practical Oncology, 2025, 39(2): 157-161.
[4]	CHEN Xingyan, LI Xue, FU Qiang. Research progress of RNA methylation in lung cancer [J]. Journal of Practical Oncology, 2024, 38(6): 421-426.
[5]	HE Jiaying, ZHU Jinli, JIA Kaixuan, YANG Peiying. Research progress of IFN-γ in the treatment of tumor immune checkpoint inhibitors [J]. Journal of Practical Oncology, 2024, 38(5): 330-335.
[6]	HAN Jing, GUAN Quanlin. Research progress of tumor-associated neutrophils in immune checkpoint inhibitors resistance [J]. Journal of Practical Oncology, 2024, 38(5): 349-354.
[7]	ZHU Gongjian, GUO Hongyun, BAI Yue, WANG Xiaomin, ZHU Xiaokang, LIU Dongyan, LIU Yuqin. The correlation between microRNA let-7a-3 methylation and IGF-Ⅱ expression in esophageal squamous cell carcinoma [J]. Journal of Practical Oncology, 2024, 38(3): 173-178.
[8]	ZHAO Lu, ZHANG Zhengfeng, WANG Dazhen, YANG Liu, LIU Ze, LOU Changjie. The current application status of immunotherapy in solid tumors [J]. Journal of Practical Oncology, 2024, 38(1): 55-61.
[9]	LI Fucheng, JIA Siyuan, BA Yuling, LUO Danli, XIAO Min. Research progress of immune checkpoint inhibitors in neoadjuvant therapy of early breast cancer [J]. Journal of Practical Oncology, 2023, 37(4): 367-371.
[10]	LONG Chaolian, LI Kun, LIU Zichen, ZHANG Nana, CHE Nanying. The correlation between the expression of programmed death ligand 1 in non-small cell lung cancer and clinical pathological features and common driver gene mutation [J]. Journal of Practical Oncology, 2023, 37(2): 117-122.
[11]	YANG Lei, ZHANG Zhengfeng, WANG Dazhen, LOU Changjie. Real-world retrospective controlled study of first-line standard chemotherapy combined with immune checkpoint inhibitor versus standard chemotherapy for advanced esophageal squamous cell carcinoma [J]. Journal of Practical Oncology, 2022, 36(6): 538-543.
[12]	LIU Qianqian, SHANG Lihua. Research progress on the correlation between immune-related adverse reactions and efficacy of immunotherapy in advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2022, 36(5): 463-467.
[13]	DONG Lin, LIU Xin, LU Hailing. Research progress of anti-angiogenic therapy combined with immune checkpoint inhibitors in advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2022, 36(4): 351-355.
[14]	ZHENG Yanli, HE Jianxia. Research progress of DNA methylation in diffuse large B-cell lymphoma [J]. Journal of Practical Oncology, 2022, 36(3): 259-262.
[15]	YANG Nan, WANG Zhao, ZHANG Yu, ZHANG Yunyan. Research progress of SMYD2 in malignant tumors [J]. Journal of Practical Oncology, 2022, 36(3): 273-277.

Research progress in epigenetic aberrant in classic Hodgkin lymphoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments